BC’s heterogeneity led to its disease classification into hormone receptor-positive, including estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+); human epidermal growth factor receptor 2 (HER2+); and triple-negative BC (TNBC) [2]. This evidence concerns the gene PGR and breast cancer.